IncobotulinumtoxinA 50U & 100U | CE-Marked | 60+ Countries
From $229.00 / vial
4.9 / 5.0 - 198 reviews
Select Products
Merz International's CE-marked IncobotulinumtoxinA - the same clinically proven naked toxin as Xeomin, trusted in 60+ countries worldwide
Bocouture is Merz Aesthetics' international brand name for IncobotulinumtoxinA - the identical active molecule as Xeomin, which carries FDA approval in the United States. CE-marked and approved in over 60 countries across Europe, Asia, Latin America, and the Middle East, Bocouture is one of the world's most widely used botulinum toxin type A products. Its hallmark advantage is its uniquely purified "naked toxin" formulation - free from complexing proteins - delivering a highly pure, stable neurotoxin with a long shelf life and minimal immunogenic potential.
Also see: Xeomin naked toxin | Official info: Merz Aesthetics
Bocouture is Merz Aesthetics' international name for IncobotulinumtoxinA - the same active molecule marketed as Xeomin in the US. CE-marked and approved in more than 60 countries, Bocouture is a globally respected botulinum toxin type A product with an unmatched purity profile. Its "naked toxin" formulation strips away the complexing proteins (hemagglutinins, non-hemagglutinin proteins) that surround the toxin in other products like Botox or Dysport, leaving only the purified 150 kDa neurotoxin molecule.
This unique purity carries two significant clinical advantages: a dramatically reduced risk of secondary non-response from antibody formation, and an extended shelf life stability - particularly relevant for international markets and practices maintaining lower product turnover. The same 1:1 unit equivalence with Botox (per muscle) simplifies dosing conversion for practitioners transitioning from OnabotulinumtoxinA.
| Product Name | Bocouture |
| Active Ingredient | IncobotulinumtoxinA (Botulinum Toxin Type A, pure neurotoxin) |
| Vial Sizes | 50 units / 100 units per vial |
| Manufacturer | Merz Pharmaceuticals GmbH (International brand) |
| Regulatory Status | CE-Marked - Approved 60+ countries |
| Indications | Glabellar lines, lateral canthal lines, forehead lines (aesthetic); cervical dystonia, blepharospasm (therapeutic) |
| Onset of Action | 3-5 days; full effect at 2 weeks |
| Duration | 3-4 months (aesthetic); varies for therapeutic |
| Shelf Life | Up to 36 months unopened at room temperature |
| Excipients | Human serum albumin, sucrose (no animal-derived complexing proteins) |
Pricing is subject to change. For licensed practitioners only.
Bocouture uses the same unit dosing as Xeomin and Botox (1:1 equivalence per muscle group). The practitioner plans injection sites and total unit dose. For glabellar lines: typically 20U total (4 injection points x 5U). For crow's feet: 12U per side. The 50U vial is ideal for targeted single-zone treatments; the 100U vial covers full-face sessions.
Reconstitute the lyophilized powder with 0.9% preservative-free sodium chloride. Common dilutions: 2.5 mL saline ? 4U per 0.1 mL (standard aesthetic); 1.25 mL saline ? 8U per 0.1 mL (higher concentration for resistant muscles). Use reconstituted product within 24 hours (refrigerated at 2-8C).
The purified IncobotulinumtoxinA molecule enters the motor nerve terminal and cleaves SNAP-25 - the same mechanism as all botulinum toxin type A products. Because Bocouture carries no complexing proteins, the naked 150 kDa toxin acts with precision, with no immune cross-reactivity from protein contaminants. The result is reliable, consistent neuromuscular blockade.
Dynamic wrinkle reduction begins within 3-5 days, reaching full effect at 2 weeks. Results last 3-4 months. Bocouture's protein-free formulation is particularly beneficial for patients who have developed secondary non-response (resistance) to protein-containing toxins - pure toxin formulations have clinically demonstrated lower antibody formation rates.
Bocouture is the ideal choice for practices serving international patients, practitioners with a patient base that travels globally for treatment, and injectors seeking to reduce secondary non-response risk in long-term neurotoxin patients. It is particularly well suited for patients with prior Botox secondary resistance (antibody-mediated), as switching to the protein-free IncobotulinumtoxinA formulation often restores full treatment efficacy.
See Important Safety Information below.
Bocouture and Xeomin are the same product - identical active ingredient (IncobotulinumtoxinA), identical formulation, identical mechanism of action, and identical dosing. The difference is purely regulatory and geographic: Xeomin is the brand name approved by the FDA for use in the United States, while Bocouture is the CE-marked international brand name used in Europe, Asia, Latin America, the Middle East, and 60+ other countries.
Bocouture offers three unique advantages: (1) It is a "naked toxin" - free from all complexing proteins, dramatically reducing the risk of antibody formation and secondary non-response. (2) It has the longest shelf life of any botulinum toxin type A product - stable at room temperature for up to 36 months unopened. (3) For patients who have developed secondary resistance to Botox or Dysport, switching to Bocouture frequently restores full treatment efficacy since the immune system's antibodies target the complexing proteins, not the toxin itself.
Bocouture (IncobotulinumtoxinA) has been demonstrated to be equivalent to Botox (OnabotulinumtoxinA) at a 1:1 unit ratio per muscle group in head-to-head clinical studies. However, individual patient response may vary, and practitioners transitioning from other neurotoxins should follow current clinical dosing guidelines and their own experience. Bocouture is NOT interchangeable in dosing with Dysport (AbobotulinumtoxinA), which uses Speywood units.
Bocouture results typically last 3-4 months for aesthetic indications (glabellar lines, crow's feet, forehead), comparable to Botox at equivalent dosing. Duration depends on injection site, muscle mass, dose, and patient metabolism. Retreatment is typically recommended around the 3-month mark for optimal maintenance of outcomes.
Yes - this is one of Bocouture's key clinical applications. Secondary non-response to Botox or Dysport is caused by antibody formation targeting the complexing proteins in those formulations. Because Bocouture contains only the pure neurotoxin with no complexing proteins, these pre-existing antibodies do not bind to it, restoring full treatment efficacy in many previously resistant patients. Published clinical literature supports IncobotulinumtoxinA as the preferred option for managing secondary non-responders.
The FDA-approved US counterpart - same pure toxin, same Merz precision
From $245.00 / vial
The naked toxin in a 50U precision vial - targeted single-zone treatments
From $138.00 / vial
The newest FDA-approved neurotoxin - Korean precision with global Phase 3 data
From $239.00 / vial
Important Safety Information